Natera Inc.: Strong Execution in Revenue Per Test Powering Our Optimism!

Natera Inc. presented its fourth quarter 2024 financial results, signaling a robust period for the company as they continue to expand and enhance their operations. The company’s revenues for the quarter reached $476 million, marking a substantial 53% increase year-on-year and exceeding their January pre-announcement by $4 million. This robust revenue growth is attributed to an increase in test volumes across their product lines, with a particular highlight on the 60% clinical volume growth of Signatera compared to the fourth quarter of 2023. The company’s gross margins improved significantly to 63%, a notable increase from 51% a year prior, reflecting successful cost control measures and improved pricing.